



Supplementary figures




eFigure 1. Knockdown of circPDS5B alleviates ischemic injury in pMCAO mice.

The mouse model of IS was established by pMCAO surgery, and pLVX-sh-circPDS5B was injected to interfere with circPDS5B expression (5 mice/group). A: apoptosis rate; B: protein levels of VEGFA and ANGPT2 in the brain tissue of mice. Scale bar = 50um. * $P < 0.05$.







eFigure 2. Reduction of circPDS5B promotes angiogenesis in HBMECs under OGD treatment.

Si-circPDS5B was transfected into HBMECs prior to OGD induction. A: apoptosis rate; B: migration; C: angiogenesis; D: protein levels of VEGFA and ANGPT2 in HBMECs. Scale bar = 50um. * $P < 0.05$.




eFigure 3. CircPDS5B targets miR-223-3p and circPDS5B affects angiogenesis of ODG-treated HBMECs by regulating miR-223-3p.

A: protein levels of VEGFA and ANGPT2 in HBMECs; B: effect of si-circPDS5B on miR-223-3p expression in HBMECs. C: the viability of circPDS5B affects angiogenesis of ODG-treated HBMECs by regulating miR-223-3p; D: the migration of circPDS5B affects angiogenesis of ODG-treated HBMECs by regulating miR-223-3p; Scale bar = 50um. * $P < 0.05$.

A**B****C****D**

eFigure 4. CircPDS5B affects angiogenesis of ODG-treated HBMECs by regulating miR-223-3p.





miR-223-3p mimic/inhibitor and pcDNA 3.1-circPDS5B were transfected into HBMECs prior to OGD treatment. A: migration; B: angiogenesis; C,D: protein levels of VEGFA and ANGPT2 in HBMECs. Scale bar = 50um. * $P < 0.05$.



eFigure 5. A targeted relation between miR-223-3p and NOTCH2.


A: NOTCH2 expression in the brain tissue; B,C: effect of miR-223-3p on NOTCH2 expression in HBMECs;

* $P < 0.05$.

A**B****C****D**

eFigure 6. CircPDS5B affects angiogenesis of OGD-treated HBMECs by miR-223-3p/NOTCH2 axis.

Si-circPDS5B, miR-223-3p inhibitor, pcDNA 3.1-NOTCH2 and si-NOTCH2 were co-transfected into HBMECs prior OGD treatment. A: NOTCH2 expression; B: apoptosis rate; C: migration; D: angiogenesis. Scale bar = 50um. * $P < 0.05$.



eFigure 7. CircPDS5B affects angiogenesis of OGD-treated HBMECs by miR-223-3p/NOTCH2 axis.

A,B: protein levels of VEGFA and ANGPT2. * $P < 0.05$.